Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) has been given a $118.00 target price by research analysts at Piper Jaffray Companies in a research note issued to investors on Tuesday. The firm presently has a “buy” rating on the specialty pharmaceutical company’s stock. Piper Jaffray Companies’ price target indicates a potential upside of 121.10% from the company’s current price.

A number of other equities analysts have also recently weighed in on the company. Royal Bank Of Canada set a $94.00 price target on Eagle Pharmaceuticals and gave the stock a “buy” rating in a report on Sunday, July 16th. Zacks Investment Research upgraded Eagle Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, July 10th. BidaskClub upgraded Eagle Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, June 21st. ValuEngine upgraded Eagle Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Tuesday, May 16th. Finally, Mizuho decreased their price target on Eagle Pharmaceuticals from $66.00 to $57.00 and set an “underperform” rating for the company in a report on Thursday, May 25th. Two analysts have rated the stock with a sell rating, two have issued a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. Eagle Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $90.00.

Shares of Eagle Pharmaceuticals (EGRX) traded down 23.80% during mid-day trading on Tuesday, reaching $53.37. 1,862,111 shares of the company were exchanged. The stock has a 50 day moving average price of $75.97 and a 200-day moving average price of $77.70. Eagle Pharmaceuticals has a 12 month low of $42.33 and a 12 month high of $97.15. The stock has a market capitalization of $816.45 million, a P/E ratio of 8.39 and a beta of 1.48.

Eagle Pharmaceuticals (NASDAQ:EGRX) last posted its earnings results on Monday, May 8th. The specialty pharmaceutical company reported $1.42 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.44 by $0.02. The business had revenue of $76.80 million for the quarter, compared to analyst estimates of $70.10 million. Eagle Pharmaceuticals had a return on equity of 79.25% and a net margin of 44.48%. The firm’s revenue for the quarter was up 159.5% compared to the same quarter last year. During the same period last year, the company posted ($0.06) EPS. Analysts predict that Eagle Pharmaceuticals will post $3.66 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Eagle Pharmaceuticals, Inc. (EGRX) PT Set at $118.00 by Piper Jaffray Companies” was published by American Banking News and is the property of of American Banking News. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark & copyright law. The correct version of this story can be read at https://www.americanbankingnews.com/2017/07/26/eagle-pharmaceuticals-inc-egrx-pt-set-at-118-00-by-piper-jaffray-companies.html.

In other news, CFO Pete A. Meyers acquired 350 shares of Eagle Pharmaceuticals stock in a transaction that occurred on Monday, June 12th. The shares were purchased at an average cost of $71.49 per share, for a total transaction of $25,021.50. Following the completion of the purchase, the chief financial officer now directly owns 350 shares of the company’s stock, valued at approximately $25,021.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have purchased 805 shares of company stock worth $61,790 over the last 90 days. 19.50% of the stock is currently owned by company insiders.

Large investors have recently modified their holdings of the company. BNP Paribas Arbitrage SA raised its stake in shares of Eagle Pharmaceuticals by 15.0% in the first quarter. BNP Paribas Arbitrage SA now owns 1,548 shares of the specialty pharmaceutical company’s stock valued at $128,000 after buying an additional 202 shares in the last quarter. State of Alaska Department of Revenue raised its stake in shares of Eagle Pharmaceuticals by 78.9% in the second quarter. State of Alaska Department of Revenue now owns 1,592 shares of the specialty pharmaceutical company’s stock valued at $125,000 after buying an additional 702 shares in the last quarter. Mason Street Advisors LLC raised its stake in shares of Eagle Pharmaceuticals by 10.2% in the first quarter. Mason Street Advisors LLC now owns 1,895 shares of the specialty pharmaceutical company’s stock valued at $157,000 after buying an additional 175 shares in the last quarter. Municipal Employees Retirement System of Michigan raised its stake in shares of Eagle Pharmaceuticals by 6.7% in the second quarter. Municipal Employees Retirement System of Michigan now owns 1,910 shares of the specialty pharmaceutical company’s stock valued at $151,000 after buying an additional 120 shares in the last quarter. Finally, Bank of Montreal Can raised its stake in shares of Eagle Pharmaceuticals by 323.9% in the second quarter. Bank of Montreal Can now owns 2,497 shares of the specialty pharmaceutical company’s stock valued at $197,000 after buying an additional 1,908 shares in the last quarter.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka.

Receive News & Ratings for Eagle Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.